NCT06900192View on ClinicalTrials.gov

A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

August 31, 2029

Study Completion Date

August 31, 2029

Conditions
Primary Progressive Multiple SclerosisMultiple SclerosisMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Secondary Progressive
Interventions
BIOLOGICAL

Orca-Q

Allogeneic (donor) stem cell graft

DRUG

myeloablative regimen

Myeloablative regimen of busulfan, fludarabine, and thiotepa.

Sponsors

Collaborators (1)

Orca Biosystems, Inc.
All Listed Sponsors
collaborator

Orca Biosystems, Inc.

INDUSTRY

lead

Stanford University

OTHER